TrialSignal
Clinical trial intelligence report
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01734824
Status
SUSPENDED
Phase
PHASE4
Sponsor
Medical University of Vienna
Executive brief
Investment-Ready Snapshot
The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs. This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01734824
Indication
Bone Marrow Oedema Syndrome
Modality
small molecule
Target
Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide
Intervention
Denosumab, Teriparatide, Placebo Denosumab, Placebo Teriparatide
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.